Atlas Antibodies, a leading provider of highly validated research antibodies, has signed an agreement to acquire evitria. evitria is a quality leader within custom recombinant antibody expression serving the biopharmaceutical industry. The acquisition brings together two highly innovative companies, with double digit organic growth over the last five years, to create an antibody-focused platform, serving a wide range of customers, with combined LTM adjusted EBITDA of approximately
"Within
Following the acquisition of evitria, Atlas Antibodies will be reported as a subsidiary within
"The combination of Atlas Antibodies and evitria creates a powerful platform, providing quality-leading antibodies to a wide range of customers including biopharmaceutical companies and academia. We see ample growth opportunities and look forward to working with the company to further develop the businesses", says
Closing is expected during the third quarter of 2021.
About
About Atlas Antibodies
Atlas Antibodies is a leading, global developer of advanced reagents for biomedical research. The company originates from the Human Protein Atlas project and was founded in 2006 by researchers at the
About evitria
Founded in 2010 in
For further information:
Phone +46 70 550 3500
viveka.hirdman-ryrberg@investorab.com
Magnus Dalhammar, Head of Investor Relations,
Phone +46 73 524 2130
magnus.dalhammar@investorab.com
Our press releases can be accessed at www.investorab.com
Investor, founded by the Wallenberg family in 1916, is an engaged owner of high quality global companies. We have a long-term investment perspective. Through board participation, as well as industrial experience, our network and financial strength, we work continuously to support our companies to remain or become best-in-class. Our holdings include, among others, ABB,
https://news.cision.com/investor/r/patricia-industries--holding-atlas-antibodies-acquires-evitria--leader-in-recombinant-antibody-expre,c3389966
https://mb.cision.com/Main/1084/3389966/1448811.pdf
(c) 2021 Cision. All rights reserved., source